MyBank was formed by Ant Financial and Fosun in 2015, and now the big data and AI-enhanced online lending platform is reportedly seeking about $870m in a round that could include both corporates at a $3.5bn valuation. Its other existing investors include Wanxiang, a contributor to the $644m the company received at the time of its launch.
After much speculation, Indonesian bank Bank Negara Indonesia has officially launched its venture capital unit, BRI Ventures. It has provided an initial $100m for the unit that it intends to eventually increase to up to $250m, and it will be headed by Nicko Widjaja, the ex-CEO of one of the country’s other notable corporate venturing entities, Telkom Indonesia’s MDI Ventures. That’s an interesting development considering MDI was said to be helping BNI put together the fund.
Chinese online lending platform 9f has filed to go public in the US and hopes to raise $150m in proceeds but, in an unusual move, is yet to settle on an exchange (it’s a fight between NYSE and Nasdaq). The company’s investors include Susquehanna International Group and SBI, though neither have stakes sized at 5% or more. Founded in 2006, 9f operates a peer-to-peer lending marketplace for consumers, with the loans supplied by both private investors and institutional partners. The platform also offers securities trading and big data analytics functionalities. The company had 76.7 million registered users as of March this year, 7.8 million of which have an approved credit limit. Its outstanding loan balance totalled $8.2bn at the time.
Alizé Pharma 3, a France-based biopharmaceutical startup based on research at University of North Carolina (UNC) at Chapel Hill, University of Maine and Harvard University, secured $74.6m on Tuesday in a series A round led by investment firm LSP. Novo Ventures, Partners Innovation and Sham Innovation Santé, respective investment vehicles for pharmaceutical firm Novo, healthcare provider Partners Healthcare and insurer Sham, among others, also took part in the round. Alizé Pharma 3 is developing drugs that are intended to treat metabolic diseases and diseases of the endocrine system.
Swiggy is in what’s increasingly become a head-to-head battle with Zomato for dominance in India’s on-demand food delivery sector, and it’s reportedly close to raising between $700m and $750m in a round led by existing investor Naspers.
Healthcare software provider Babylon Health has announced a $550m series C round that will value it at $2bn post-money once it formally closes.
Traveloka raised $420m in a GIC-backed round in April, and is reportedly talking to investors in a bid to secure an additional $500m at a valuation of about $4.5bn.
Mobile bank operator Nubank has already sealed funding, notching up $400m in a series F round that included Tencent. The corporate had already invested $90m in Nubank last October, together with a $90m secondary transaction.
Online real estate brokerage Compass is now valued at $6.4bn having secured $370m in a series G round that included SoftBank Vision Fund, fresh from the launch of its recent $108bn second vehicle.
Mobile commerce platform Wish is now valued at $11.2bn following a series H round reportedly sized at $300m. General Atlantic led the round, without any other participanys being disclosed.
Machine learning software provider DataRobot has reportedly secured $200m in a series E round led by Sapphire Ventures at a valuation of more than $1bn.
Chinese engineering equipment rental service Zhongeng United has raised a total of about $167m in new funding, almost $22m of which came in the shape of series B-plus capital supplied by Five Star.
Utimco, a joint investment company of University of Texas and Texas A&M University, has backed a $234m life sciences fund raised by Germany-based venture firm Wellington Partners.
There’s been a lot of talk of decline in the new media sector as of late, and we could be about to see some more consolidation in the space. Vice is one of the biggest players and is reportedly in discussions to acquire Refinery29 in a move intended to diversify its comparatively masculine reputation.